Recipharm has entered into a long term agreement with Sato Pharmaceutical for the commercial manufacture and delivery of Emla Patch to Japan.
Emla Patch is used as a local anaesthetic product and will be launched under the business area of ethical pharmaceuticals at Sato.
Recipharm’s facility in Karlskoga, Sweden will produce and deliver to Sato. After a launch in Japan, it is expected that the annual volumes of Emla Patch to Sato will be a significant addition to the present production at the Karlskoga facility.
“We first established a business relationship with Sato in 2012 and this new supply agreement extends our partnership further. We are looking forward to the launch in Japan and cooperating with Sato in developing the business, to the benefit of both companies,” said Ingela Palmkvist, General Manager at Recipharm in Karlskoga.